Each critical advance—from the discovery of ROS1 fusions as a biomarker in NSCLC and the approval of crizotinib as the first ROS1-targeted therapy to the characterization of resistance mechanisms and development of next-generation ROS1 inhibitors—has tangibly improved outcomes. Here, ROS1 is linked to non-small cell lung carcinoma.